Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Nurs. 2012 May 10-23;21(9):S13-7.

Cabazitaxel for prostate cancer: patient preparation and ongoing care.

Author information

1
University Hospitals, Bristol NHS Foundation Trust.

Abstract

Cabazitaxel, a new-generation taxane that fulfils a hitherto unmet need for second-line chemotherapy in metastatic castrate-resistant prostate cancer, has received approval from the European Medicines Agency. In a recent phase III clinical trial, this drug showed a survival benefit over mitoxantrone; however, it was associated with significant side effects, most notably neutropenia, diarrhoea, nausea/vomiting, peripheral neuropathy and fatigue. Careful patient selection for cabazitaxel is essential, as is a robust management plan for the detection, assessment and prompt treatment of any side effects. This article examines the nurse's role in patient preparation, education, ongoing monitoring and support throughout cabazitaxel treatment.

PMID:
22690408
DOI:
10.12968/bjon.2012.21.Sup6.S13
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center